Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68


Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures.

Husain AM, Lee JW, Kolls BJ, Hirsch LJ, Halford JJ, Gupta PK, Minazad Y, Jones JM, LaRoche SM, Herman ST, Swisher CB, Sinha SR, Palade A, Dombrowski KE, Gallentine WB, Hahn CD, Gerard EE, Bhapkar M, Lokhnygina Y, Westover MB; Critical Care EEG Monitoring Research Consortium.

Ann Neurol. 2018 Jun;83(6):1174-1185. doi: 10.1002/ana.25249.


Clinical and electrocorticographic response to antiepileptic drugs in patients treated with responsive stimulation.

Skarpaas TL, Tcheng TK, Morrell MJ.

Epilepsy Behav. 2018 Jun;83:192-200. doi: 10.1016/j.yebeh.2018.04.003. Epub 2018 Apr 30.


Assessment of the correlations of lacosamide concentrations in saliva and serum in patients with epilepsy.

Brandt C, Bien CG, Helmer R, May TW.

Epilepsia. 2018 Apr;59(4):e34-e39. doi: 10.1111/epi.14023. Epub 2018 Feb 16.


Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.

Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM.

J Clin Psychopharmacol. 2017 Dec;37(6):675-683. doi: 10.1097/JCP.0000000000000780.


Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study.

Misra UK, Dubey D, Kalita J.

Epilepsy Behav. 2017 Nov;76:110-113. doi: 10.1016/j.yebeh.2017.07.005. Epub 2017 Sep 15.


Wake up to sleep: The effects of lacosamide on daytime sleepiness in adults with epilepsy.

Foldvary-Schaefer N, Neme-Mercante S, Andrews N, Bruton M, Wang L, Morrison S, Bena J, Grigg-Damberger M.

Epilepsy Behav. 2017 Oct;75:176-182. doi: 10.1016/j.yebeh.2017.08.002. Epub 2017 Sep 1.


Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy.

Nakhutina L, Kunnakkat SD, Coleman M, Lushbough C, Arnedo V, Soni N, Grant AC.

Epilepsy Behav. 2017 Aug;73:90-94. doi: 10.1016/j.yebeh.2017.05.001. Epub 2017 Jun 14.


Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes.

Baulac M, Coulbaut S, Doty P, McShea C, De Backer M, Bartolomei F, Vlaicu M.

Epileptic Disord. 2017 Jun 1;19(2):186-194. doi: 10.1684/epd.2017.0907.


Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy.

Lindauer A, Laveille C, Stockis A.

Clin Pharmacokinet. 2017 Nov;56(11):1403-1413. doi: 10.1007/s40262-017-0530-8.


Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension.

Wechsler RT, Yates SL, Messenheimer J, Leroy R, Beller C, Doty P.

Epilepsy Res. 2017 Feb;130:13-20. doi: 10.1016/j.eplepsyres.2016.12.015. Epub 2016 Dec 29.


Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.

Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M.

Lancet Neurol. 2017 Jan;16(1):43-54. doi: 10.1016/S1474-4422(16)30292-7. Epub 2016 Nov 24. Erratum in: Lancet Neurol. 2017 Feb;16(2):102.


Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study.

Hong Z, Inoue Y, Liao W, Meng H, Wang X, Wang W, Zhou L, Zhang L, Du X, Tennigkeit F; EP0008 Study Group.

Epilepsy Res. 2016 Nov;127:267-275. doi: 10.1016/j.eplepsyres.2016.08.032. Epub 2016 Sep 1.


Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.

Baulac M, Byrnes W, Williams P, Borghs S, Webster E, De Backer M, Dedeken P.

Acta Neurol Scand. 2017 Apr;135(4):434-441. doi: 10.1111/ane.12691. Epub 2016 Oct 6.


Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.

Vossler DG, Wechsler RT, Williams P, Byrnes W, Therriault S; ALEX-MT study group.

Epilepsia. 2016 Oct;57(10):1625-1633. doi: 10.1111/epi.13502. Epub 2016 Aug 16.


Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine.

Meador KJ, Loring DW, Boyd A, Echauz J, LaRoche S, Velez-Ruiz N, Korb P, Byrnes W, Dilley D, Borghs S, De Backer M, Story T, Dedeken P, Webster E.

Epilepsy Behav. 2016 Sep;62:267-75. doi: 10.1016/j.yebeh.2016.07.007. Epub 2016 Aug 10.


Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial.

Elger CE, Rademacher M, Brandt C, Elmoufti S, Dedeken P, Eckhardt K, Tennigkeit F, De Backer M.

Epilepsy Behav. 2016 Sep;62:1-5. doi: 10.1016/j.yebeh.2016.05.023. Epub 2016 Jul 15.


The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy.

Lancman ME, Fertig EJ, Trobliger RW, Perrine K, Myers L, Iyengar SS, Malik M.

Epilepsy Behav. 2016 Aug;61:27-33. doi: 10.1016/j.yebeh.2016.04.049. Epub 2016 Jun 14.


Intravenous lacosamide in clinical practice-Results from an independent registry.

Lang N, Lange M, Schmitt FC, Bös M, Weber Y, Evers S, Burghaus L, Kellinghaus C, Schubert-Bast S, Bösel J, Lammers T, Sabolek M, van Baalen A, Dziewas R, Kraft A, Ruf S, Stephani U.

Seizure. 2016 Jul;39:5-9. doi: 10.1016/j.seizure.2016.01.008. Epub 2016 Jan 12.


Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial.

Meador KJ, Yang H, Piña-Garza JE, Laurenza A, Kumar D, Wesnes KA.

Epilepsia. 2016 Feb;57(2):243-51. doi: 10.1111/epi.13279. Epub 2016 Jan 1.

Supplemental Content

Loading ...
Support Center